a Accumulating evidence suggests that vesicular glutamate transporters (VGLUTs), which control the storage and release of glutamate, may play a role in pain processing. Chicago sky blue 6B (CSB6B), which is structurally related to glutamate, is a competitive VGLUT inhibitor without affecting plasma membrane transporters. The present study was designed to investigate the antinociceptive effects of CSB6B in a number of pain models. The hot-plate test was used as an acute thermal pain test. Inflammatory pain was evaluated using acetic acid writhing, formalin, and complete Freund's adjuvant tests. Intracerebroventricular administration of CSB6B did not affect acute thermal pain responses in 50 or 558C hot plate tests. However, CSB6B attenuated acetic acid-induced writhing in a dose-dependent and time-dependent manner. In addition, CSB6B reduced licking/biting behavior during the second phase, but not during the first phase, following an intraplantar injection of formalin. In the complete Freund's adjuvant test, a significant attenuation of thermal hyperalgesia was also observed in CSB6B-treated mice.
Accumulating evidence suggests that vesicular glutamate transporters (VGLUTs), which control the storage and release of glutamate, may play a role in pain processing. Chicago sky blue 6B (CSB6B), which is structurally related to glutamate, is a competitive VGLUT inhibitor without affecting plasma membrane transporters. The present study was designed to investigate the antinociceptive effects of CSB6B in a number of pain models. The hot-plate test was used as an acute thermal pain test. Inflammatory pain was evaluated using acetic acid writhing, formalin, and complete Freund's adjuvant tests. Intracerebroventricular administration of CSB6B did not affect acute thermal pain responses in 50 or 558C hot plate tests. However, CSB6B attenuated acetic acid-induced writhing in a dose-dependent and time-dependent manner. In addition, CSB6B reduced licking/biting behavior during the second phase, but not during the first phase, following an intraplantar injection of formalin. In the complete Freund's adjuvant test, a significant attenuation of thermal hyperalgesia was also observed in CSB6B-treated mice.
At antinociceptive doses, CSB6B did not affect mice spontaneous locomotor activity. The present study shows that pharmacological inhibition of VGLUT activity was sufficient to attenuate experimental inflammatory pain and suggests that regulation of VGLUTs might be a novel therapeutic strategy for the treatment of pain. 
Introduction
Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system and plays critical roles in various physiological and pathological processes (Watkins, 2000) . The concentration of glutamate in the synaptic cleft is mainly regulated by two families of transporters. Following exocytotic release, glutamate is rapidly taken up from the extracellular space by plasma membrane-associated transporters termed excitatory amino acid transporters (EAATs). After entry into the nerve terminal, glutamate is packaged into synaptic vesicles by vesicular glutamate transporters (VGLUTs). Therefore, it is widely considered that EAATs determine the termination of synaptic effects of glutamate whereas VGLUTs are responsible for the storage and release of glutamate (Shigeri et al., 2004; Thompson et al., 2005) .
Many pain states are associated with increased extracellular levels of glutamate (Johnson, 1978; Renno, 1998) , and regulation of the glutamate system has been suggested to be a strategy for the treatment of pain (Fundytus, 2001; Wozniak et al., 2012) . There is some evidence that inhibition of glutamate release contributes toward the effects of some analgesic agents (Coderre et al., 2007) . Intrathecal, intracerebral, or systemic administration of glutamate receptor antagonists (at either ionotropic or metabotropic receptors) attenuates both acute and chronic pain in rodents (Fundytus, 2001) . Moreover, manipulation of the activity of glutamate transporters has also been shown to affect pain behaviors (Maeda et al., 2008; Yaster et al., 2011) . However, no pharmacological study has investigated the antinociceptive effect of reduced glutamate release by targeting VGLUTs.
Chicago sky blue 6B (CSB6B), which is structurally related to glutamate, is a competitive VGLUT inhibitor that does not affect plasma membrane transporters (Roseth et al., 1995) . Recently, several researchers, including the present authors, attempted to further understand the role of VGLUTs in neural function and behavior by applying CSB6B as a pharmacological tool (Baghbanzadeh et al., 2010; He et al., 2013) . Intracerebroventricular (i.c.v.) administration of CSB6B increased food intake in Ross 208 broilers, and its effect was associated with an inhibition of glutamate release. Pretreatment with CSB6B also attenuated methamphetamine-induced hyperactivity and behavioral sensitization in mice. In this study, we evaluated the antinociceptive effects of CSB6B in a number of animal models, with a focus on its effects on inflammatory pain. Haley and McCormick (1957) . The injection volume was 5 ml/animal. After completion of behavioral testing, brains were removed by rapid decapitation and the distribution of CSB6B was examined. Only the mice with distribution of CSB6B in the ventricles were included in the data analysis ( Fig. 1 ).
Hot plate test
ICR mice were individually placed on the surface of a hot plate (HUGO SACHS Elektronik-Harvard Apparatus GmbH, March-Hugstetten, Germany) maintained at 50 or 55±0.11C. The latency was recorded from the start to the end point of jumping, licking, or shaking the hind paws. A cutoff time of 60 s was set to prevent the possibility of tissue damage. All mice were used only once and tested before and at different times after i.c.v. administration.
Acetic acid writhing test
Kunming mice were injected intraperitoneally with 0.4 ml of 0.6% acetic acid, and the number of writhes, characterized by a wave of contractions of the belly, followed by extension of the hind limbs, was recorded from 5 to 20 min after the injection of acetic acid. To analyze the dose dependence of the effect of CSB6B, three different doses were applied (0.2, 1.0, and 5.0 mg/ animal) and antinociception was determined 2 h after i.c.v. administration. To determine the time dependence of the effect, mice were administered CSB6B (5.0 mg i.c.v.) and tested 0.5, 2, and 6 h later.
Formalin test
ICR mice were administered CSB6B (5.0 mg i.c.v.) 2 h before the formalin test. Then, an intraplantar (i.pl.) injection of 20 ml of 2% formalin was administered into the right hindpaw. The time spent on licking or biting the injected paw was recorded in 0-5 min (first phase) and 15-30 min (second phase) as neurogenic and inflammatory pain, respectively.
Complete Freund's adjuvant test
Thermal sensitivity was measured using a plantar test device (Model 390G; IITC Life Science Inc., Woodland Hills, California, USA) according to the method described by Hargreaves et al. (1988) . Kunming mice were placed in Plexiglas chambers on a heated (301C) glass surface and allowed to habituate for 1 h for 2 days. A mobile radiant heat source was then positioned under the plantar surface of the hindpaw and the latency was recorded from the start to the end point of paw withdrawal. A cutoff time of 20 s was set to prevent the possibility of tissue damage. For each time point, each mouse was tested three times with an interval of at least 2 min and the latencies of the three repetitions were averaged. Testing during grooming or exploratory behavior was avoided (Callahan et al., 2008) .
To induce persistent inflammatory pain, 20 ml of complete Freund's adjuvant (CFA) (F5881, Sigma-Aldrich) was injected i.pl. into the right hind paw. The withdrawal latency was recorded before and 24 h after CFA injection. Then, CSB6B (5.0 mg i.c.v.) was administered and the latency was recorded at different times thereafter.
Locomotor activity
Kunming mice were allowed to habituate to the experimental environment and handling 1 day before testing. On the testing day, mice were administered with aCSF or CSB6B (0.2, 1.0, 5.0 mg i.c.v.) and placed individually in Plexiglas boxes (40 Â 40 Â 35 cm). Behavior was recorded for 180 min by a ceiling video camera and analyzed using an EthoVision video tracking system (Noldus, Wageningen, The Netherlands). The distribution of Chicago sky blue 6B in the ventricular system after intracerebroventricular administration.
Statistical analysis
Data were expressed as the mean±SEM. Multiple comparisons were performed by one-way analysis of variance (ANOVA) or repeated-measures two-way ANOVA, followed by the Bonferroni post-hoc test. The level of statistical significance was defined as P value less than 0.05.
Results
Effect of Chicago sky blue 6B on hot-plate latency
The hot-plate test was performed at two stimulus intensities (50 or 551C) to assess the effect of CSB6B on acute thermal pain responses. As shown in Fig. 2 , the higher temperature resulted in a lower latency in aCSFtreated and CSB6B-treated mice. However, the latency in the two groups of mice was not significantly different across the observation period at either low [F(1,90) = 0.70; NS] or high [F(1,90) = 0.23; NS] stimulus intensity.
Effect of Chicago sky blue 6B on acetic acid-induced writhing
The effect of CSB6B on acetic acid-induced writhing was dose and time dependent. As shown in Fig. 3a , CSB6B at the doses of 0.2, 1.0, and 5.0 mg/animal produced 56.3, 82.4, and 93.2% inhibition of the pain behavior, respectively. One-way ANOVA showed a significant effect of treatment [F(3,36) = 5.10; P < 0.01]. A Bonferroni posthoc test indicated that the effect of CSB6B was significant at 1.0 or 5.0 mg/animal (P < 0.05), but not at 0.2 mg/ animal. Figure 3b shows the effect of CSB6B at different time points. One-way ANOVA showed a significant effect of time [F(3,36) = 3.69; P < 0.05]. A Bonferroni post-hoc test indicated that the effect of CSB6B was significant 2 h (P < 0.05), but not 0.5 and 6 h after administration.
Effect of Chicago sky blue 6B on formalin-induced pain Figure 4 shows the effect of CSB6B on the formalininduced pain response during the first and second phases. The time spent on licking or biting the formalin-injected paw in aCSF-treated or CSB6B-treated mice was comparable during the first phase, but different during the second phase. Repeated-measures two-way ANOVA showed a significant effect of treatment [F(1,19) = 4.93; P < 0.05] but not time [F(1,19) = 0.26; NS] and a significant between treatment Â time interaction [F(1,19) = 8.51; P < 0.01]. A Bonferroni post-hoc test indicated that the effect of CSB6B was significant during the second phase, producing 60.1% inhibition of the pain behavior (P < 0.05).
Effect of Chicago sky blue 6B on complete Freund's adjuvant-induced thermal hyperalgesia Figure 5 shows the changes in thermal thresholds in response to CFA and CSB6B. Twenty-four hours after i.pl. injection of CFA, the withdrawal latency was significantly decreased compared with the baseline. Then, the mice were i.c.v. administered aCSF or CSB6B. i.c.v. administration of aCSF did not affect the withdrawal latency across the observation period. However, CFA-induced thermal hyperalgesia was attenuated in CSB6B-treated mice. Repeated-measures two-way ANOVA showed significant effects of treatment [F(1,64) = 4.72; P < 0.05] and time [F(4,64) = 39.56; P < 0.001] and a significant interaction [F(4,64) = 5.80; P < 0.001]. A Bonferroni post-hoc test indicated that the effect of CSB6B was significant at 2 h after administration (P < 0.05).
Effect of Chicago sky blue 6B on locomotor activity
Locomotor activity was measured to assess possible sedative effects that could influence the response to pain. CSB6B had no significant effect on locomotor activity at the three doses tested [F(3,32) = 1.33; NS] (Fig. 6) .
Discussion
Over the years, a large number of studies have addressed the involvement of glutamatergic neurotransmission in acute and chronic pain. However, most of them focused on glutamate receptors or EAATs (Fundytus, 2001) . Recently, several studies investigated the relationship between VGLUTs and acute or chronic pain using genetically modified mice (Moechars et al., 2006; Leo et al., 2009; Lagerström et al., 2010; Liu et al., 2010) . Heterozygous mice with a partial deficiency of VGLUT2 showed an attenuation or absence of some neuropathic pain features and VGLUT2-dependent thalamic signaling was considered to be potentially associated with the behavioral changes (Moechars et al., 2006; Leo et al., 2009) . It has also been reported that restricted VGLUT2 deficiency in subpopulations of dorsal root ganglion neurons resulted in a reduced responsiveness to various pain stimuli, including inflammatory pain (Lagerström et al., 2010; Liu et al., 2010) . However, these results from genetically modified mice may be confounded by multiple factors, such as adaptation and compensation during development, and there has been no previous study investigating the role of VGLUTs in pain signaling by pharmacological means.
In this study, we investigated the effects of CSB6B, a VGLUT inhibitor, on pain responses in a number of experimental models. Phasic pain was observed in the hot-plate test and during the first phase of the formalin test, and tonic pain was measured in writhing and CFA tests and during the second phase of the formalin test. Consistent with the results from VGLUT2-deficient mice (Moechars et al., 2006; Leo et al., 2009) , i.c.v. administration of CSB6B did not affect the acute phasic pain. However, tonic chemically induced pain behaviors, which Data are expressed as the mean±SEM, n = 10-11. *P < 0.05, compared with aCSF-treated mice. are considered to be more relevant to clinical pain (Le Bars et al., 2001) , were significantly attenuated in CSB6B-treated mice. The differences in the effects of CSB6B on phasic and tonic pain may be because of differences in the mechanisms and regulation of these two pain types (Le Bars et al., 2001; Wu et al., 2005) , and the effects of CSB6B may be related to the regulation of excessive glutamate neurotransmission during the process of pain sensitization.
The effects of CSB6B on chemically induced tonic pain seem to be in contrast to previous studies showing that formalin-induced or carrageenan-induced inflammatory pain was not affected in heterozygote VGLUT1 and VGLUT2 mice (Leo et al., 2009) . A possible explanation would be that the actions of glutamate might vary in different areas of the nervous system as the expression of the corresponding transporters was reduced across the entire nervous system in heterozygous mice, whereas the effect of CSB6B after i.c.v. administration is restricted. In addition, it should be noted that CSB6B showed similar activity for all VGLUT isoforms (Shigeri et al., 2004; Thompson et al., 2005) . Therefore, it is also possible that a deficiency of VGLUT1 or VGLUT2 is not sufficient and an inhibition of more than one isoform is required for the attenuation of inflammatory pain. Further efforts are needed to differentiate the effects of each isoform and this would be considerably enhanced by the development of isoform-selective compounds.
Given the well-established role of the glutamate system in pain signaling, it would be of great interest to develop strategies to regulate glutamate neurotransmission for pain treatment. However, direct blockade of postsynaptic ionotropic glutamate receptors, including NMDA, AMPA, and KA receptors, does not seem to be desirable because these receptors are distributed widely in the nervous system. With the sole exception of selective NR2B antagonists, most ionotropic glutamate receptor blockers have been associated with sedative, cognitive, ataxic, and psychotomimetic side-effects (Fundytus, 2001; Chiechio et al., 2004; Collins and Chessell, 2005) . Metabotropic glutamate receptors hold some promise as targets owing to their ability to modulate rather than mediate excitatory neurotransmission (Chiechio and Nicoletti, 2012 ). Another strategy to rectify the glutamate overflow during persistent pain is to regulate membrane glutamate transporters, which remove extracellular glutamate by transporting the neurotransmitter into the cytoplasm. b-Lactam antibiotics, such as ceftriaxone, promote the expression of glutamate transporters and their analgesic efficacy has been reported in preclinical and clinical studies (Hu et al., 2010; Macaluso et al., 2013) . Recently, an upstream modulation of glutamate release by glutamate carboxypeptidase, which cleaves neuropeptide NAAG into NAA and glutamate, has also been proposed as an attractive therapeutic strategy (Wozniak et al., 2012) . Regulation of VGLUT activity represents an alternative way to modulate the glutamate release, which may therefore affect pain processing. The present study confirmed this prediction by showing that treatment with CSB6B, a competitive VGLUT inhibitor, attenuated inflammatory pain responses in a number of animal models. In addition, the observations that VGLUT2-deficient mice showed attenuated pain response with no impairment in memory and learning, neuromotor performance, or anxiety are likely to lend support for antagonism of VGLUT2-mediated glutamatergic transmission as a potential target for the treatment of pain (Moechars et al., 2006) .
In conclusion, we showed that pharmacological inhibition of VGLUT activity was sufficient to attenuate the pain induced by various chemical stimuli. The present study showed that presynaptic VGLUTs play a role in pain regulation, especially in inflammatory pain, and suggests the possibility of VGLUT inhibition as a therapeutic strategy for the treatment of pain. 
